| P2093 | author name string | Di Wu | |
| | Anlong Xu | |
| | Yong Ren | |
| | Shangwu Chen | |
| | Chongyang Duan | |
| | Fenfang Wu | |
| P2860 | cites work | Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia | Q46214607 |
| | The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. | Q51546501 |
| | An elementary introduction to Bayesian computing using WinBUGS. | Q52064633 |
| | A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients | Q67962240 |
| | Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes | Q23671265 |
| | Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis | Q24606203 |
| | The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies | Q26853348 |
| | Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group | Q28141496 |
| | All-trans-retinoic acid in acute promyelocytic leukemia | Q28250406 |
| | Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia | Q33187375 |
| | Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome | Q33389149 |
| | Retinoic acid and arsenic trioxide for acute promyelocytic leukemia | Q33409020 |
| | Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience | Q34088767 |
| | AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance | Q34169298 |
| | All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia | Q34546653 |
| | A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL9 | Q34577969 |
| | Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group | Q34621685 |
| | Acute promyelocytic leukemia: from highly fatal to highly curable | Q34755208 |
| | Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies | Q35612977 |
| | Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis | Q35618167 |
| | An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid | Q35910751 |
| | Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 |
| | Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia | Q37117735 |
| | Use of indirect and mixed treatment comparisons for technology assessment | Q37259556 |
| | Checking consistency in mixed treatment comparison meta-analysis | Q37705195 |
| | Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses | Q39735046 |
| | Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. | Q40231478 |
| | Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial | Q41347785 |
| | High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. | Q43278789 |
| P433 | issue | 30 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| | leukemia | Q29496 |
| P304 | page(s) | 47319-47331 | |
| P577 | publication date | 2016-06-17 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia | |
| P478 | volume | 7 | |